The immune defense is dependent on coordinated movement of leukocytes between blood and affected tissues. An inflammatory response is characterized by initial extravasation of granulocytes into challenged areas. During the extravasation process, a blood-borne granulocyte first makes transient tethering contacts with endothelial cells, which lead to rolling of the cell along the vessel wall. If the granulocyte receives appropriate activation signals, it is able to adhere to the vessel wall in a shear-resistant manner. This firmly bound granulocyte can then ultimately seek for interendothelial cell junctions and transmigrate between the endothelial cells into the tissue to execute its effector functions (1, 2) .
According to the prevailing multistep model, the extravasation cascade is regulated by sequential interplay of different adhesion and signaling molecules (1) (2) (3) . Selectins and their mucin-type counter receptors mediate initial tethering and rolling interactions (4, 5) . The activation signals are thought to be conveyed by chemokine binding to their serpentine receptors (6) . This triggers a switch of preexisting leukocyte integrins into a higher avidity stage, which then mediate stable adhesion by binding to endothelial members of the immunoglobulin superfamily (7, 8) . The molecular mechanisms of the transmigration step remain poorly characterized (9) .
Vascular adhesion protein 1 (VAP-1) (1) is a homodimeric endothelial sialoglycoprotein that belongs to a subgroup of monoamine oxidases (10, 11) . These semicarbazide-sensitive monoamine oxidases catalyze oxidative deamination of primary amines in a reaction whose physiological substrates and biological effects remain mysterious (12) (13) (14) . They are strikingly distinct from monoamine oxidases A and B with respect to their amino acid sequence, subcellular localization, cofactors, substrate and inhibitor specificity, and physiological function. We have shown in vitro that VAP-1 is involved in lymphocyte binding to high endothelial venules that support lymphocyte, but not granulocyte, extravasation during physiological recirculation (15, 16) . In those assays with frozen tissue sections, VAP-1 had only a minimal, if any, role in granulocyte adhesion to endothelial cells. The potential roles of VAP-1 in the granulocyte extravasation cascade and its function in inflammatory reactions in vivo have remained unresolved.
The aim of the present study was to analyze the involvement of VAP-1 in granulocyte accumulation at sites of inflammation in vivo. Moreover, since hydrodynamic shear caused by the blood flow is a critical parameter in all leukocyte-endothelial cell interactions in vivo and cannot fully be modeled in in vitro experiments, we wanted to elucidate the position of VAP-1 during the extravasation cascade using intravital mi-croscopy. Our results show that if VAP-1 is rendered nonfunctional by monoclonal antibodies (mAbs), there is a dramatic reduction in the number of granulocytes infiltrating into an inflamed tissue. We further demonstrate that during granulocyte-endothelial cell interactions, VAP-1 has an important role in the initial rolling step, which leads to clear effects on stable adhesion and extravasation. The current results advance our understanding of development of an inflammatory response and regulation of granulocyte extravasation. Moreover, the biological function of VAP-1 suggests that semicarbazide-sensitive monoamine oxidases can regulate granulocyte trafficking, which is the first clearly defined physiological function for these enzymes.
MATERIALS AND METHODS

Monoclonal and chimeric antibodies
Mouse mAbs TK8 -14 (IgG2a) and 2D10 (IgG1) against different epitopes of human VAP-1 have been described (17) . Hermes-3 against human CD44 (18), which does not crossreact with rabbits, served as an isotype-matched control for TK8 -14. An anti-CD31 mAb cross-reacting with rabbits was obtained from Dako (Glostrup, Denmark).
The construction of chimeric (Ch) anti-VAP-1 mAbs will be described elsewhere in more detail (M.-L. Laukkanen et al., unpublished results). In brief, the variable regions of the heavy chain of TK8 -14 and 2D10 were amplified by reverse transcription-polymerase chain reaction using total RNA from the parental hybridoma cells as templates and degenerate 5Ј and 3Ј primers (19) . Similarly, using degenerate light-chain 5Ј primers and the reverse 3Ј kappa primer, the light chains of these antibodies were amplified. To construct chimeric antibodies, the variable regions of heavy and light chains were subcloned into mammalian expression vectors containing human heavy-chain constant regions (modified ␥ 2 isotype) and a light-chain constant region (kappa), respectively, and a mouse heavy-chain promoter and a signal sequence. The CH2 domain has been modified in this vector to lack complement activating and Fc receptor binding abilities, and thus is devoid of all natural effector functions (20) . A control chimeric (ChNPLys) was done analogously using the variable region of the light chain from a mAb against 4-hydroxy-3-nitrophenylacetyl and the variable region of a heavy chain from a mAb specific to lysozyme.
Mammalian vectors containing the chimeric heavy-chain and light-chain expression cassettes were cotransfected into a nonsecreting rat myeloma cell line YB2/0 by electroporation. The antibody-producing clones were selected with ELISA. The chimeric antibodies were produced in stable transfectants and purified from the conditioned culture medium by protein A Sepharose affinity chromatography and acidic elution. After neutralization and dialysis, the concentration of the chimeric Ab was measured using bicinchoninic acid protein assay. Hence, the resulting chimeric mAbs contain the variable regions of mouse light and heavy chain grafted into an effector function-deficient human IgG2 framework.
Immunohistochemistry and immunoblottings
Acetone-fixed frozen sections from rabbit organs were stained with an indirect immunoperoxidase technique (15) using mouse or chimeric mAbs at 20 g/ml as primary antibodies. The second stage reagents were peroxidase-conjugated sheep anti-mouse IgG or anti-human IgA, M, and G (Dakopatts), as appropriate. The sections were counterstained with hematoxylin and mounted in Depex.
Endothelial reactivity of anti-VAP-1 mAbs in rabbits was confirmed by ex vivo stainings. In these studies, anti-VAP-1 mAb TK8 -14 or isotype-matched negative control mAb Hermes-3 was administered intravenously (i.v.) to rabbits (2 mg/kg). Thereafter, the animals were killed and tissues were collected for preparing frozen sections. In vitro, only the second-stage peroxidase anti-mouse Ig was applied onto the sections before developing the color reaction. Thus, only if the primary antibody has bound to vascular endothelium in vivo can any positive reactivity be detected.
The molecular weight of rabbit VAP-1 was determined by immunoblotting of 1% Nonidet P-40 lysates made from rabbit liver, which is rich in VAP-1-positive endothelial cells, using enhanced chemiluminescence and a previously described protocol (10) .
Inflammatory models
Two acute granulocyte-dependent peritoneal inflammation models were used to study the role of VAP-1 in leukocyte extravasation. A strong inflammation, induced by intraperitoneal (i.p.) injection of interleukin 1 (IL-1) and proteose peptone, was used to study firm adhesion and transmigration of granulocytes. A mild local inflammation induced by superfusion of a part of exposed mesenteric membrane by IL-1 was used to study granulocyte rolling on endothelial cells. Both study protocols have been approved by the Turku Review Board for the Laboratory Animal Experimentation.
Chemical peritonitis model
New Zealand white (NZW) rabbits weighing ϳ2 kg were sedated with an intramuscular (i.m.) injection of 200 l fentanyl-fluanisone (Hypnorm) and marginal vein and central artery of the ear were cannulated. A bolus (2 mg/kg) of anti-VAP-1 mAb TK8 -14 or a control mAb Hermes-3 diluted in sterile phosphate-buffered saline (PBS) was then administered via the vein. Five minutes later, acute chemical peritonitis was induced with an i.p. injection of 25 ml sterile PBS containing 20,000 U human recombinant IL-1 (cross-reacting with rabbits) and 5% proteose peptone (21); 0.1 g of blue Sepharose 4CL beads as an indicator of a proper injection was included to the suspension. Hereafter these animals will be called peritonitis-induced rabbits. In control experiments, only PBS was injected i.p., and these animals will be referred to as sham-induced rabbits. Blood was drawn from the central artery before and at 1, 3, 5, 15, 30 min and 2 and 4 h after the mAb injection. At 4 h, the animals were prepared for surgical anesthesia (see below) and 50 ml prewarmed RPMI1640 medium was injected into the peritoneal cavity. After a standardized massage protocol, the lavage fluid was gently collected into heparin-containing tubes by drawing with a syringe connected to a plastic tubing, which was inserted into the peritoneal cavity through a small abdominal incision.
Thereafter, the animals were prepared for intravital microscopy to enable microscopic analyses of adherent and transmigrated cells in peritoneum. The mesentery was exteriorized through an abdominal midline incision and gently spread on a special microscopic stage using a previously described protocol (16) . All exposed parts were covered with saline-soaked gauze and kept moist by continuous dripping of bicarbonate-buffered superfusion medium thermo-controlled at 37°C. Leukocyteendothelial interactions were recorded in real time using digital video recorder (DHR10000NP, Sony) coupled to a CDD video camera (Hamamatsu Photonics, Hamal Su City, Japan) attached to an ocular of an Olympus BX50WI intravital microscope equipped with a water immersion objective (ϫ 20/0.5 and ϫ 10/0.3 UMPlanFl, 3.3 mm working distance).
Leukocyte counts from each animal were determined from 0.5 ml blood samples taken into EDTA-anticoagulated tubes (Capiject) using a hemocytometer (Celltac-alpha, Nihon Kohden, Japan) calibrated for rabbit cells. The volume of peritoneal lavage fluid and the presence of the blue indicator beads were recorded, and the number of peritoneal leukocytes was enumerated after trypan blue staining in cell counting chambers. Cytospins were prepared from the peritoneal cells (20,000 cells/slide) and subjected to Diff-Quick staining and differential counting.
In situ superfusion model of inflammation
In a weaker localized inflammatory model, animals were prepared for intravital microscopy of postcapillary mesenteric venules according to the published protocols (16, 22) with some modifications. Surgical anesthesia was induced to NZW rabbits with an i.m. injection of midazolam (Dormicum, 2 mg/kg) and Hypnorm (0.3 ml/kg) and maintained by repeated injections of 10% Hypnorm (3 ml/kg/h) via a cannulated marginal ear vein. Physiological saline was continuously infused i.v. with a computer-controlled syringe pump (6 ml/kg/h). To assist ventilation, a tracheostomy was performed and a tracheal tube was inserted. Carotic artery was exposed and a PE 60 catheter was inserted for blood sampling. Thereafter, a suitable branch of the mesenteric artery was chosen and dissected free, and a polyethylene catheter (PE-10) was inserted retrogradely into the vessel.
The animals were transferred to an intravital microscope and an appropriate area of mesenterium was selected for observation (see above). When feasible, two independent venules were monitored simultaneously. Inflammation was induced by superfusing the mesenteric window with recombinant human IL-1␤ (3000 U/25 ml PBS injected as multiple small boluses into the superfusion fluid) for 3 h. Blood samples were regularly drawn through the carotic cannula. Centerline velocity of the blood was measured simultaneously using a dual-photodiode method and a commercial velocimeter (CircuSoft Instrumentation, Hockessin, Del.).
Baseline recordings (10 min) were taken after injection of local intra-arterial boluses of saline. Thereafter, 3 ϫ 300 l boluses of sterile PBS containing control chimeric Ab ChNPLys (100 g/ml) or anti-VAP-1 chimeric Ab ChTK8 -14 (100 g/ml) alone or together with another anti-VAP-1 chimeric Ab Ch2D10 (100 g/ml) were given during 45 s. A 10 min period was recorded again and hemodynamic variables were measured simultaneously.
In certain experiments with both inflammation models, animals were given a 200 l i.v. bolus of acridine red (1.67 mg/ml in PBS) to stain the nuclei of leukocytes in vivo. The leukocyte-endothelial interactions of labeled polymorphonuclear and mononuclear cells were recorded using stroboscopic epi-fluorescent illumination and a silicone-intensified target camera as described in ref 16 .
Analyses of leukocyte-endothelial cell interactions
Hemodynamics were assessed as described in refs 16, 22-24. In brief, centerline velocities measured were converted to mean blood flow velocities (V b ) by multiplying with an empirical factor of 0.625. The Newtonian wall shear rates (␥) were approximated as 2.12 ϫ 8 ϫ V b /d, where d is the mean diameter of the vessel (measured from 10 different locations) and 2.12 is a median empirical correction factor. Wall shear stress () was calculated as ␥ ϫ , where is the estimated viscosity of blood at 37°C (0.012 Poise).
The videotapes were analyzed off-line for the parameters characterizing leukocyte-endothelial cell interactions, i.e., rolling, stable adhesion, and perivascular extravasation. Leukocyte rolling flux (Rf) is defined as the number of rolling cells that pass a line perpendicular to the vessel wall during 1 min. Leukocyte transit time equals the time measured for a given cell to travel 100 m in the vessel and is used to count the leukocyte velocity in m/s (100 m/transit time). Transit velocity distributions are expressed as number of cells falling into successive 1 m/s velocity classes (1, 2, 3, 4. . . 100). Changes in the transit velocity were also analyzed by combining events in 20 successive classes into bigger ones (1-20, 21-40. . . ) to get enough cells into each class. The median transit velocity was defined as the 1 m/s class in which cumulative frequency of cells reached 50%.
Rolling patterns were determined for individual successive leukocytes using frame-by-frame analyses. The number of interactions that each leukocyte had with the venular wall within a defined 100 m vessel segment was scored as follows: 0 ϭ continuous rolling (no change in the rolling pattern; the cell enters and leaves the segment as a rolling cell without any intermittent jumps), 1 ϭ one tethering or detachment event (the cell either enters the segment in a free flow and makes one contact with endothelial layer which results in continuous rolling until the cell leaves the segment or the cell enters the segment as a rolling cell, which then detaches into the free flow during its transit through the segment). Each attachment or detachment event is thus assigned value 1 and the sum is counted for each cell during its transit through the segment. So if a leukocyte enters as a free-flowing cell, tethers to the endothelium, rolls for a while, makes a jump and binds to the endothelium again, and leaves the segment by rolling, it gets a score 3 (two attachments and one detachment within the segment). For different treatments, the mean scores for all cells analyzed before and after Ab injections were counted.
The number of stably adherent leukocytes was determined from the video recordings of the animals subjected to the 4 h chemical peritonitis. The number of leukocytes adherent per 100 m vessel wall in the areas that supported leukocyte rolling was counted from the playbacks.
The extent of leukocyte transmigration was analyzed from videotapes obtained from the peritonitis-induced and shaminduced animals. The planar surface area of mesenteric membrane where leukocytes covered Ͼ50% of the area was measured using a morphometric program (AnalySIS, Soft Imaging System, Germany).
Statistical analyses
Peritoneal leukocyte counts, areas of perivascular infiltrate, and numbers of firmly adherent cells were compared using Student's unpaired t test. The effects of chimeric Ab injections on hemodynamic parameters and on leukocyte-endothelial cell contacts were compared to the baseline values obtained from the very same vessel before the treatment using paired Student's t test. Median rolling velocities were compared using analysis of variance. Statistical significance was set at PϽ0.05.
RESULTS
Characterization of rabbit VAP-1
We found that the two function-blocking mouse mAbs TK8 -14 and 2D10 against different epitopes of human VAP-1 (17) cross-react with rabbit VAP-1. Both mAbs recognize in rabbits an antigen that displays a tissue distribution similar to that of human VAP-1. For instance, in the rabbit heart the mAbs stain vessels of different sizes (Fig. 1A) . An endothelial marker, CD31, displays a similar staining pattern. Endothelial synthesis of rabbit VAP-1 was confirmed by administering mAbs i.v. to rabbits and then staining tissue sections with the second-stage antibody only. Anti-VAP-1 mAb-treated animals showed intense luminal reactivity, whereas no signal could be detected from the animals that received the control mAb (Fig. 1B) . These data show that the primary antibody against VAP-1 has bound to the luminal surface of vascular endothelial cells in vivo. Also, the molecular mass of the rabbit VAP-1 antigen [170 kDa under nonreducing (Fig. 1C) 
VAP-1 mediates leukocyte extravasation into sites of acute inflammation
To study the role of VAP-1 in inflammation in vivo, we first elucidated whether interference of VAP-1 function with mAbs affects the net extravasation process in an acute peritonitis model. The overall extent of peritoneal inflammation was evaluated by counting the number of extravasated leukocytes in the lavage fluid. The transmigration process at the perivascular space was also directly analyzed by intravital microscopy of inflamed mesenteric membrane from the same animals.
Control animals were injected i.p. with saline only (sham-induced) and treated with an i.v. bolus (2 mg/kg) of anti-VAP-1 or isotype-matched control mAb. As expected, there were only a few leukocytes in the lavage fluid at 4 h in either control mAb or anti-VAP-1 mAbtreated sham-induced animals ( Fig. 2A) . The majority of these peritoneal cells (81% on average) were mononuclear ones (Fig. 2B) , presumably representing mostly resident macrophages. In videomicroscopic analyses, only very occasional cells in perivascular space were detectable (Fig. 2C, F 
When an acute chemical peritonitis was induced to rabbits by i.p. injection of IL-1 and proteose peptone (peritonitis-induced animals), a Ͼ20-fold increase in the number of extravasated cells in peritoneal cavity was seen in control mAb-treated animals ( Fig. 2A) . In peritonitis-induced animals, there was a significant 69% decrease in the number of extravasated granulocytes in the lavage fluid in anti-VAP-1-treated rabbits when compared to those that received the control mAb ( Fig.  2A) . Consistent with the granulocytic nature of the acute inflammation, Ͼ97% of the leukocytes were polymorphonuclears in the lavage fluid of peritonitisinduced animals (Fig. 2B) . Both anti-VAP-1 and control mAbs caused a transient drop in systemic leukocyte counts. Notably, however, the drop was recovered by 15 min in the case of anti-VAP-1 mAb but was more long-lasting with the control mAb (Fig. 2G) , and hence cannot explain the beneficial antiinflammatory effects of anti-VAP-1 treatment in the peritonitis-induced rabbits. Inhibition of leukocyte emigration into the lavage fluid also translated into a clear reduction in the extent of perivascular infiltration in the VAP-1-treated peritonitis-induced animals ( Fig. 2D-F) . Thus, blocking of VAP-1 dramatically attenuates a granulocyte-dependent inflammatory response in vivo.
Anti-VAP-1 mAb diminishes the number of firmly adherent leukocytes in inflamed vessels
The net reduction in the number of extravasated cells in VAP-1-treated animals can be due to the inhibition at the rolling, firm adhesion, or transmigration step. Therefore, using the intravital videomicroscopy, we analyzed the number of adherent cells in the mesenteric vessels of sham-induced and peritonitis-induced animals. In sham-induced rabbits, very few leukocytes were found firmly adherent to vascular wall in control mAb-treated animals, and even fewer in anti-VAP-1-treated rabbits (Fig. 3A) . In peritonitis-induced rabbits, the number of stably adherent cells was high in the control mAb-treated animals. Most important, the results showed a statistically significant 44% reduction in the number of stably bound cells in peritonitis-induced animals receiving the anti-VAP-1 mAb when compared to the control mAb-treated animals (Fig. 3A) . Intravital microscopy with fluorescently labeled leukocytes revealed that the rolling and adherent cells were almost exclusively (Ͼ98%) granulocytes in this model (Fig.  3B) . Thus, VAP-1 contributes critically to the granulocyte extravasation before the transmigration step.
Anti-VAP-1 mAbs and granulocyte rolling
A reduction in the number of firmly adherent leukocytes after anti-VAP-1 treatment can mean that rolling is normal in these animals, and the first step affected is stable adhesion, or that rolling is already impaired and consequently leads to diminished stable adhesion. The , the leukocyte aggregates (arrowheads) and scattered leukocytes (arrows) in peritonitis-induced rabbits treated with a control mAb (D), and the small perivascular cuffs of infiltrating cells in the anti-VAP-1 mAb-treated animals (E). V ϭ venule. Above the vessels, the infiltrated area (as used for measuring the area for Fig. 1F ) is outlined by a black dashed line; below the vessel, the line is omitted for clarity. Bars, 50 m. F) The surface area of the perivascular tissue infiltrated by extravasated leukocytes was analyzed by morphometry. The total length of the venules around which the infiltrated area was measured and the number of animals used are also shown. G) Systemic leukocyte counts after mAb treatments were determined at the indicated time points and compared to the baseline samples taken before infusion of mAbs (meanϮse of the change). Baseline counts in individual rabbits ranged from 4.0 to 10.3 (ϫ 10 6 /ml). 4 h peritonitis model was not useful to distinguish between these alternatives for two reasons. First, the severe inflammation with many firmly adherent cells on the vessel wall led to a situation in which most rolling took place via leukocyte-leukocyte interactions (25, 26) rather than via leukocyte rolling on endothelial cells (data not shown). Since VAP-1 is not expressed on any leukocyte, the possible role of VAP-1 on rolling would be practically impossible to detect with this model. Second, since systemic administration of both mAbs caused a transient drop in blood leukocyte counts (see above), they were not applicable to minute-by-minute analysis of rolling immediately after their infusion.
To overcome these limitations, we used genetically engineered effector function-deficient antibodies (complement fixing and Fc receptor binding capacity; ref 20) . The chimeric antibodies ChTK8 -14 and Ch2D10 were function blocking in endothelial binding assays with lymphocytes (data not shown) and showed identical tissue staining patterns in humans and rabbits when compared to the parental mouse mAbs (Fig. 1A) . The control chimeric antibody did not recognize anything in rabbits (Fig. 1A) . With these chimeric mAbs, a local infusion technique into a side branch of mesenteric artery was applied (22) to minimize systemic effects of loading animals with foreign proteins and due to a low yield of the chimeric mAb. We also developed a model of less severe inflammation in which almost all rolling occurs between granulocytes and endothelial cells by locally superfusing mesenteric membrane with IL-1 containing buffer under an intravital microscope. In this in situ inflammation model, the number of rolling cells was 46 Ϯ 12 cells/min immediately after the surgery. Control or anti-VAP-1 chimeras had no effect on surgery-induced leukocyte rolling on endothelial cells. The number of rolling cells significantly increased to 85 Ϯ 21 cells/min (nϭ14, Pϭ0.005) after a 3 h IL-1 superfusion. After this stimulation, Ͼ94% of the rolling cells were granulocytes ( Fig. 4A-C) . Administration of either control or anti-VAP-1 chimeras had no significant effects on blood velocity, blood vessel diameter, shear rate, shear stress, or leukocyte counts nor did they significantly affect the number of those cells which rolled at velocity Ͻ100 m/s. (Table 1, Fig. 4D-F ) .
VAP-1 blockade regulates the rolling velocity of granulocytes in vivo
Using the local superfusion model of inflammation, it was apparent from intravital videomicroscopy that the velocity of the rolling cells was faster after anti-VAP-1 mAb infusion. The rolling velocity is a critical parameter in regulation of the adhesion cascade for determining the time a leukocyte is exposed to local activating stimuli at an inflammatory focus. Slow rolling velocity is required for an integrin-mediated stable adhesion to take place (1) . Therefore, after a 3 h IL-1 superfusion, chimeric mAbs were injected via the mesenteric artery and the velocity of individual rolling cells was determined in detail 3 min and 10 min later.
Treatment with the control chimeric Ab had no effect on the velocity of rolling cells at the 3 min time point (Fig.  5) . In contrast, the rolling velocity increased significantly in animals subjected to one or both anti-VAP-1 chimeric Ab. This can be seen from the cumulative rolling velocity profiles (Fig. 5A-C) in which the velocity of each individual leukocyte is determined. The same increase in the rolling velocity after neutralization of VAP-1 was clearly evident from pooled analyses of the distribution of leukocytes in different velocity classes (Fig. 5D-F) . When using a median rolling velocity as a single representative variable, there was a 20% increase after administration of the anti-VAP chimeric Ab ChTK8 -14 (Fig. 5G) . A more pronounced 35% increase was seen if both anti-VAP-1 chimeras were applied simultaneously. Ten minutes after injection of the control chimeric antibody ChTK8 -14 and ChTK8 -14ϩCh2D10, a 4, 10, and 54% increase in the median rolling velocities, respectively, were seen. Thus, blocking of VAP-1 causes a sustained increase in granulocyte rolling velocity.
VAP-1 is needed for smooth uninterrupted rolling of granulocytes
The change in the rolling velocity could be due either to an increase in the velocity of continuously rolling cells or to a change in the rolling behavior (frequency and duration of rolling contacts and jumps during transit in the vessel). To distinguish between these two possibilities, the number of attachments and detachments of each leukocyte interacting with the vessel wall was enumerated. During the control period, the majority of cells displayed relatively uninterrupted smooth rolling or only a few jumps (Fig. 6) . When the function of VAP-1 was blocked with ChTK8 -14, alone or together with Ch2D10, rolling became much jerkier (Fig.  6) . Thus, functionally active VAP-1 is needed to secure the granulocyte contacts with the vessel wall during the rolling phase of the extravasation cascade.
DISCUSSION
We show here that VAP-1 is important for granulocyte extravasation in vivo. Intact VAP-1 is needed to mediate continuous slow rolling, which is a prerequisite for stable adhesion. When the function of VAP-1 is blocked, the net effect is severe impairment of granulocyte emigration into areas of inflammation. The current results provide a notable extension to the biological role of VAP-1 for granulocyte trafficking in vivo. VAP-1, and therefore semicarbazide-sensitive monoamine oxidases in general, thus constitute a new element in controlling the first line of immune defense.
Peritonitis is a well-established model for an acute granulocyte-dependent inflammation. In the present study, two different inflammatory models were used where the vast majority of rolling and transmigrating cells were granulocytes. The chemical peritonitis causes a brisk inflammation with numerous slowly rolling, adherent, and transmigrating cells. It revealed that ablation of VAP-1 function significantly reduces the number of stably bound and extravasated leukocytes. Nevertheless, it requires loading of animals with milligram quantities of mAbs and shows a prominent component of leukocyte-leukocyte rolling, which even theoretically cannot be inhibited by anti-VAP-1 mAbs. The in situ inflammatory model with a local infusion technique, on the other hand, was designed to dissect leukocyte tethering and rolling of leukocytes directly on endothelial cells with small amounts of locally administered antibodies under mild inflammatory conditions. In this setting, VAP-1 proved to be important already for the very initial granulocyte-endothelial contacts. In contrast to many published reports using intravital microscopy, it should be noted that in this model we were able to analyze the very same vessels with both isotype-matched control and anti-VAP-1 mAbs and to perform careful kinetic analyses of hemodynamic variables throughout the experiments. The inflammatory response in peritoneum is markedly impaired after neutralizing the function of several adhesion molecules. On the endothelial side, the inflammatory response is attenuated by 40 -80% when P-selectin, E-selectin, or ICAM-1 are separately rendered nonfunctional (27, 28) . Nevertheless, an almost complete inhibition is seen only when ICAM-1 and P-selectin (29) or both E-and P-selectin are inactivated simultaneously (27, 30) . These data illustrate well the redundancy of the mechanisms operative at the successive steps of the vital multistep adhesion cascade. Thus, the ϳ70% inhibition seen after VAP-1 blockade is highly significant and may be further enhanced by additional coinhibition of other relevant adhesion molecules. The present results are the first evidence that inhibition of VAP-1 reduces the inflammatory response in an in vivo animal model.
Intravital microscopy revealed that VAP-1 is needed to reduce the rolling velocity of granulocytes during inflammation. In that sense, its function is reminiscent of that of E-selectin (CD62E). When the function of inflammationinduced E-selectin is neutralized, the mean rolling velocity of granulocytes in mice increases (23, 31) . In rabbits, neutralization of E-selectin by a 10 min in situ incubation under no-flow conditions also increased the absolute rolling velocity in the mesenterium (32) . Hence, VAP-1 and E-selectin are probably important as a braking mechanism, which reduces the velocity of rolling cells enough for the leukocytes to survey the endothelial cells for signs of inflammation, that is needed for activation and subsequent stable adhesion.
The stepwise component of rolling is thought to be regulated by dissociation of clusters of receptor-ligand bonds (33) . Thus, the characteristic jerky rolling seen after VAP-1 blockade suggests that the bond between VAP-1 and its ligand contributes critically to these clusters.
Alternatively, VAP-1 can regulate the dissociation of other receptor-ligand bonds (presumably those of selectins) mediating tethering and rolling. Although the regulatory role of VAP-1 might involve its enzymatic function, which catalyzes the formation of a signaling molecule H 2 O 2 and an aldehyde (11), the antibody-dependent inhibition most likely involves another mode of action since the mAbs used do not inhibit monoamine oxidase activity of this dual-function molecule.
The rolling flux did not diminish after VAP-1 blockade. Since this parameter describes how many cells pass a certain line in the vessel within a given time, it is affected by the number of rolling cells as well as their velocity. Thus, if the number of rolling cells remains the same and the rolling velocity increases, it actually increases the rolling flux. This is the case after E-selectin blockade, which results in a 1.8-fold increase in the rolling flux (34) . Hence, the 35-54% increase in rolling velocity observed in the absence of increased rolling flux after VAP-1 blockade means that the number of rolling cells must decrease. We hypothesize that a more rigorous saturation of VAP-1 by function-blocking antibodies would also lead to an actual decrease in the number of rolling cells as a consequence of the increased rolling velocity. In fact, when the effect of anti-VAP-1 chimeric Abs was analyzed in vessels with rapidly rolling (ϳ100 m/s) cells, there was a ϳ45% decrease in the absolute number of rolling cells. These data suggest that when the endothelial binding avidity of the fast rolling cells is further weakened by ablating the VAP-1 function, the cells will be released into the noninteracting pool of leukocytes.
Since interference with VAP-1 affected extravasation more than rolling or stable adhesion, it suggests that VAP-1 could play a role during the transmigration step as well. This would be compatible with its expression in pericytes (35) . Interaction of leukocytes with endothelial or pericyte VAP-1 could normally assist their transmigration during this last phase of the multistep adhesion cascade. In this case, VAP-1 could share functions with CD31, which is thought to play a critical role at this step. When the function of this adhesion and signaling molecule is blocked by mAbs, the number of rolling or adherent cells does not change, but the cells are trapped at the basement membrane during the subsequent transmigration process (36 -39) .
In conclusion, our results show that a semicarbazidesensitive monoamine oxidase, VAP-1, plays an important role in granulocyte extravasation in vivo. In fact, its function as an endothelial molecule regulating leukocyte adhesion is the first physiological function ascribed to this family of molecules. Blocking of VAP-1 function with Abs increases the rolling velocity, which translates into reduction of firm adhesion and ultimately into a significant impairment of the emigration response of granulocytes at sites of inflammation. The chimeric anti-VAP-1 antibodies developed here will be useful for further clinical trials as a novel anti-adhesive tool.
We are indebted to Drs. Klaus Ley and Uli von Andrian for teaching us the local cannulation techniques. The expert Figure 6 . VAP-1 blockade causes jerky rolling. The number of endothelial interactions for a leukocyte during its transit through a 100 m segment of the vessel was counted as described in Materials and Methods during the baseline and 3 min after the administration of control or anti-VAP-1 chimeric Abs. n ϭ the absolute number of assessed leukocytes from 3 representative animals using the IL-1 superfusion model. The statistical significance of each treatment in comparison to the baseline (before mAb) is shown above the bars.
